ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Hillary S. Andrews(Friends of Cancer Research), Jeff Allen(Friends of Cancer Research), Diana Merino Vega(AstraZeneca (Japan)), Carin R. Espenschied(Guardant (United States)), Sameera R. Wijayawardana(Eli Lilly (United States)), Samuel Hong(Agilent Technologies (United States)), Névine Zariffa(Alliance for Decision Education), Antje Hoering(Cancer Research And Biostatistics), Anna M. Szpurka(Eli Lilly (United States)), Minakshi Guha(Vedantra Pharmaceuticals (United States)), Geoffrey R. Oxnard(Foundation Medicine (United States)), Mark Stewart(Friends of Cancer Research), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Gary A. Pestano(SpectraDynamics (United States)), Nicole Krämer(Boehringer Ingelheim (Germany)), Li Liu(Illumina (United States)), Emily Goren(Cancer Research And Biostatistics), Stephanie H. Choi(Merck Serono S.p.A. (Italy)), Katherine K. Nishimura(Cancer Research And Biostatistics), Brittany A. McKelvey(Friends of Cancer Research), Christine K. Ward(Takeda (United States)), Lynne Poole(AstraZeneca (United Kingdom)), Adam Rosenthal(Cancer Research And Biostatistics), Shibing Deng(Pfizer (United States)), Megan Eisele(Cancer Research And Biostatistics), Jean-François Martini(Pfizer (United States))
Cited by 19
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
|Nature Genetics|2014|1.1k
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
|Journal of Clinical Oncology|2018|925
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879